These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31737895)

  • 1. Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma.
    Ong SY; Phipps C; Kaur H; Tan L; Lee YS
    Ann Acad Med Singap; 2019 Sep; 48(9):298-300. PubMed ID: 31737895
    [No Abstract]   [Full Text] [Related]  

  • 2. Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate.
    Sekiguchi Y; Wakabayashi M; Takizawa H; Iizuka H; Sakajiri S; Sugimoto K; Inano T; Fukuda Y; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Komatsu N; Noguchi M
    J Clin Exp Hematop; 2020; 60(1):26-28. PubMed ID: 32224563
    [No Abstract]   [Full Text] [Related]  

  • 3. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
    O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
    J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature.
    Ma H; Bhagat G; O'Connor OA
    Leuk Lymphoma; 2019 Dec; 60(13):3300-3303. PubMed ID: 31184235
    [No Abstract]   [Full Text] [Related]  

  • 5. Hematology: relapsed and refractory PTCL--into the therapeutic abyss.
    Foss F
    Nat Rev Clin Oncol; 2011 Jun; 8(6):321-2. PubMed ID: 21468128
    [No Abstract]   [Full Text] [Related]  

  • 6. Pralatrexate for refractory or recurrent subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome.
    Ware O; Tarabadkar ES; Shustov A; Shinohara MM
    J Am Acad Dermatol; 2020 Feb; 82(2):489-491. PubMed ID: 31319088
    [No Abstract]   [Full Text] [Related]  

  • 7. Thoracic subcutaneous infiltration: an unusual presentation of subcutaneous panniculitis-like T-cell lymphoma.
    Ballanger F; Barbarot S; Le Gouill S; Gaillard F; Cassagnau E; Lodé L; Dréno B; Stalder JF
    Acta Derm Venereol; 2009; 89(4):427-9. PubMed ID: 19688166
    [No Abstract]   [Full Text] [Related]  

  • 8. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
    Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
    Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
    Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
    Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA approves pralatrexate for treatment of rare lymphoma.
    Thompson CA
    Am J Health Syst Pharm; 2009 Nov; 66(21):1890. PubMed ID: 19850775
    [No Abstract]   [Full Text] [Related]  

  • 12. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
    Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
    Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review.
    Chen CC; Teng CL; Yeh SP
    Ann Hematol; 2016 Apr; 95(5):837-40. PubMed ID: 26873089
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): preliminary results from the T-Cell Consortium trial.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):6-7. PubMed ID: 24852788
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
    Amengual JE; Lichtenstein R; Lue J; Sawas A; Deng C; Lichtenstein E; Khan K; Atkins L; Rada A; Kim HA; Chiuzan C; Kalac M; Marchi E; Falchi L; Francescone MA; Schwartz L; Cremers S; O'Connor OA
    Blood; 2018 Jan; 131(4):397-407. PubMed ID: 29141948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.
    O'Connor OA; Amengual J; Colbourn D; Deng C; Sawas A
    Leuk Lymphoma; 2017 Nov; 58(11):2548-2557. PubMed ID: 28738754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions.
    Marneros AG; Grossman ME; Silvers DN; Husain S; Nuovo GJ; MacGregor-Cortelli B; Neylon E; Patterson M; O'Connor OA; Zain JM
    Blood; 2009 Jun; 113(25):6338-41. PubMed ID: 19389878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphoma.
    Alaibac M; Berti E; Pigozzi B; Chiarion V; Aversa S; Marino F; Peserico A
    J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S121-3. PubMed ID: 15858508
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
    Li L; Duan W; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Zhang X; Chang Y; Nan F; Yan J; Li Z; Young KH; Zhang M
    Br J Haematol; 2017 Sep; 178(5):772-780. PubMed ID: 28597542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous panniculitislike T-cell lymphoma with hemophagocytosis: complete remission with BFM-90 protocol.
    Medhi K; Kumar R; Rishi A; Kumar L; Bakhshi S
    J Pediatr Hematol Oncol; 2008 Jul; 30(7):558-61. PubMed ID: 18797207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.